Short answer
Edwards Lifesciences (EW) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results released on July 23, 2026.
Edwards Lifesciences 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results released on July 23, 2026
- Investor focus: quarterly performance details in Exhibit 99.1
- Item 2.02 disclosure highlights current operating results and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q2 sales $1.74B, up 13.6%; constant-currency growth 12.5%, indicating broad-based structural-heart momentum
- TMTT sales $195.9M, up 47.3%; faster-growing PASCAL and EVOQUE platforms increasingly diversify beyond TAVR
- Adjusted EPS $0.78 versus $0.67; adjusted operating margin 30.0% versus 28.2%, supported by stronger sales and investment timing
- 2026 guidance raised: constant-currency sales growth 10%-11%, TAVR growth 8%-9%, TMTT sales $760M-$780M
- GAAP EPS $0.42 affected by $188.2M tax valuation allowance and $40.0M impairment; adjusted EPS guidance reaffirmed at $2.95-$3.05
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edwards Lifesciences 8-K filings
Get the next EW 8-K as it lands
Follow EW for push alerts, or ask the research agent what this filing means.